Compare SAR & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAR | PROK |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.9M | 316.0M |
| IPO Year | 2006 | 2021 |
| Metric | SAR | PROK |
|---|---|---|
| Price | $16.80 | $1.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $23.75 | $7.40 |
| AVG Volume (30 Days) | 133.1K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 14.34% | N/A |
| EPS Growth | ★ 14.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $17.00 | $1.30 |
| 52 Week High | $24.76 | $3.48 |
| Indicator | SAR | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 29.78 | 41.68 |
| Support Level | N/A | $1.56 |
| Resistance Level | $23.77 | $2.01 |
| Average True Range (ATR) | 0.35 | 0.12 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 6.48 | 13.48 |
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.